uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
27.22
-0.59 (-2.12%)
Nov 24, 2025, 2:21 PM EST - Market open
uniQure Employees
uniQure had 209 employees as of December 31, 2024. The number of employees decreased by 271 or -56.46% compared to the previous year.
Employees
209
Change (1Y)
-271
Growth (1Y)
-56.46%
Revenue / Employee
$75,364
Profits / Employee
-$1,125,100
Market Cap
1.70B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 209 | -271 | -56.46% |
| Dec 31, 2023 | 480 | -21 | -4.19% |
| Dec 31, 2022 | 501 | 38 | 8.21% |
| Dec 31, 2021 | 463 | 131 | 39.46% |
| Dec 31, 2020 | 332 | 84 | 33.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
QURE News
- 7 days ago - Diamond Hill International Strategy Q3 2025 Performance Review - Seeking Alpha
- 10 days ago - uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - QURE - PRNewsWire
- 12 days ago - QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 14 days ago - From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside - Seeking Alpha
- 14 days ago - uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 18 days ago - uniQure to Announce Third Quarter 2025 Financial Results - GlobeNewsWire
- 21 days ago - UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Data - Benzinga